Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05090722

A Pilot Study to Evaluate PureWick for Nocturia

This is a single-center prospective pilot study of PureWick used as a management for nocturia and reduction of nighttime falls associated with going to the bathroom. Subjects are followed up to 3 months after the intervention. As a pilot study, it is expected that a 3-month follow-up will adequately capture urinary and sleep outcomes data and any adverse events related or unrelated to the study device.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Nocturia Lower Urinary Tract Symptoms Pathological Conditions, Signs and Symptoms Signs and Symptoms Urological Manifestations

Age range

50 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Weill Cornell Medicine, New York, United States

Loading trial locations.

About this study

Nocturia is a highly prevalent condition among older adults, significantly affecting the quality of life as well as putting them at an increased risk of falls and fractures. In those 65 and older, accidental falls are identified as the leading cause of injury and death. The chance of falling increases from 30% to 50% with age greater than 85 years.

A study identified that in 1508 ambulatory men and women, nighttime urination of 2 times at night is associated with increased risk of falls (OR=1.84, 95% CI 1.05-3.22), with significantly higher risks when it increased to 3 or more times at night (OR=2.15, CI 95% -1.04-4.44). Incontinence management that reduces the need to get out of bed will lead to reduced risk of falls and unintentional injury fatalities.

The PureWick Urine Collection System is intended for non-invasive urine output management. It pulls urine through tubing that is connected to a collection canister for proper disposal. It is designed to be used by patients, caregivers, or healthcare professionals in both home environments and professional care facilities.

The PureWick System allows individuals to void while still in bed, demonstrating the potential to reduce the risks of falls associated with nighttime voids in men and women with nocturia. We hypothesize that this will also improve sleep quality and overall quality of life.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women aged 50 years or older.
  • Experiences 2 or more voids per night as assessed on a 3-day bladder diary.

Exclusion criteria

  • Compromised skin integrity in the perineal area (e.g., ulcers, open wounds, etc.).
  • Neurological impairment or psychiatric disorder preventing proper understanding of consent.
  • Unable to operate the PureWick system.
  • Unable to complete required questionnaires and diaries.
  • Investigator deems subject as unsuitable for enrollment.

Treatment and study plan

PureWick System

Device

The PureWick system consists of the external catheter, collection tubing, and collection canister with lid. It operates via a power cord that is plugged into the device outlet and the A/C power outlet.

Other names: PureWick Urine Collection System device, PWF030F

Primary outcomes

  1. The proportion of patients at 3 months who have a demonstrated 50% or greater reduction in the number of nocturia episodes/night

    Time frame: 3 months

    The proportion of patients at 3 months who have a demonstrated 50% or greater reduction in the number of nocturia episodes/night will be calculated via binomial proportions and an exact (Clopper-Pearson) 95% confidence interval will be computed to assess the precision of the obtained estimate.

  2. Change in average number of nocturnal voids at baseline and at 3 months

    Time frame: At baseline and 3 months

    The paired t-test or Wilcoxon signed-rank test will be used, as appropriate, to compare the average number of nocturnal voids between baseline and at 3 months.

  3. Change of scores on the N-QoL at baseline and at 3-months

    Time frame: At baseline and 3 months

    N-QoL (Nocturia quality of life) score is determined by the n-qol short form. The ICIQ-Nqol is a patient-completed questionnaire evaluating quality of life (QoL) in patients with nocturia for use in research and clinical practice across the world. The ICIQ-Nqol is the N-QoL adapted for use within the ICIQ structure and provides a detailed and robust measure to assess the impact of nocturia on quality of life with particular reference to the effects on patient' lives of Nocturia and can be used as an outcome measure to assess impact of different treatment modalities.

    0-52 overall score with greater values indicating increased impact on quality of life Bother scale not incorporated into overall score but indicate impact of symptoms overall for the patient.

    Similar analyses to paired t-test or Wilcoxon signed-rank test will be performed to compare scores on the N-QoL, an self-reported sleep quality between baseline and at 3-months.

Secondary outcomes

  1. Change in the incidence of urinary tract infection (UTI) at baseline and 3 months

    Time frame: At baseline and 3 months

    McNemar's chi-square test will be used to compare the incidence of UTI between baseline and at 3 months.

  2. Change in the incidence of pressure ulcers/skin breakdown at baseline and 3 months

    Time frame: At baseline and 3 months

    McNemar's chi-square test will be used to compare pressure ulcers/skin breakdown between baseline and at 3 months.

Study contacts

Contact information is provided by the study sponsor or research team.

Bilal Chughtai, MD

CONTACT

[email protected]

516-628-5910

Jennifer Polo, CCRC

CONTACT

[email protected]

516-628-5910

Sponsors and collaborators

Lead sponsor

Northwell Health

Other

Collaborators

  • Becton, Dickinson and Company

Registry information

Important dates

Study start
2021
Primary completion
2027
Study completion
2027
First posted
Oct 25, 2021
Registry last updated
Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.